Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

CDC Panel Releases Ruling on Meningococcal B Vaccines

by Global Biodefense Staff
June 29, 2015
Biodefense Vaccine Development

Credit: Shutterstock

The U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) last week voted for a Category B recommendation for meningococcal group B vaccination in individuals aged 16 to 23.

This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment.

The BEXSERO vaccine was approved by the U.S. FDA in January 2015 through an accelerated approval pathway for use in individuals aged 10 through 25 years and acquired by GSK in March 2015 following the closure of the three-part transaction with Novartis.

“GSK welcomes this vote as an important step forward to help protect against meningococcal disease in the U.S.,” said Patrick Desbiens, Senior Vice President, U.S. Vaccines, GSK. “Meningococcal disease is fast-moving, unpredictable and can cause irreversible damage, so vaccination is the best tool to help prevent it. Today’s vote is the latest milestone on a 20-year journey to develop a vaccine in order to help protect individuals from this devastating condition.”

Meningococcal disease is a rare but serious bacterial infection that can be difficult to diagnose within 24 hours of symptom onset, and can leave those affected with lifelong disability. According to the CDC, each year there are 800-1,200 cases of all serogroups of meningococcal disease across all ages, and with an approximate 12 percent mortality rate.

Five serogroups of Neisseria meningitidis [A, B, C, W-135 and Y] cause the majority of cases of meningococcal disease in the U.S. Meningococcal group B is one of the most prevalent serogroups, accounting for 32 percent of all reported U.S. cases in all age groups in 2013.

The ACIP also voted last week to include BEXSERO in the CDC’s Vaccines for Children (VFC) program for ages 16 through 18. The ACIP voted in February for the use of meningococcal group B vaccines in people greater than 10 years of age at increased risk for meningococcal group B disease and this was published on June 12, 2015. The recommendation endorsed today by the ACIP will become final upon publication in a future Morbidity and Mortality Weekly Report.

GSK is currently evaluating the safety and immune response of a pentavalent meningococcal vaccine (A, C, W-135, Y, plus B) which is now in Phase 2 research.

Tags: Vaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC